Fox Chase Cancer Center Announces 2018 Award Recipients for Translational Clinical Protocol Development
Fox Chase Cancer Center recently announced the awardees of the 2018 translational clinical protocol development based on basic and preclinical research results. Translational research disease groups were created with a multidisciplinary group of clinical and research-based faculty, with a focus on coordinating an ongoing assessment of translational research opportunities through investigator-initiated trials, interdisciplinary collaboration, research support, and trainee involvement. The program supports projects that are potentially paradigm-shifting; possess a high likelihood to lead to significant peer-reviewed funding; address community needs; and/or translate laboratory findings into new clinical treatments.
2018 Award Recipients
- Margaret von Mehren, MD, and Lori Rink, PhD, for their proposal, “Evaluation of Imatinib with ARQ092 Alone or in Combination with a PD-1 Inhibitor in Advanced Gastrointestinal Stromal Tumors”
- Joshua Meyer, MD, and Edna Cukierman, PhD, for their study, “Utilizing Pulsed Low-Dose–Rate Radiation to Prevent Radiation-Induced Stromal Activation: A Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial”
- Margie Clapper, PhD, and Michael Hall, MD, for their project, “Prevention of Colorectal Adenomas in Patients With Lynch Syndrome Using Atorvastatin and Aspirin: An Exploratory Biomarker Trial”
- Yanis Boumber, MD, PhD, and Suraj Peri, PhD, for their project, “Prospective Clinical Study of SCLC Patients With NSD1, NSD2 Mutations Receiving Platinum Doublet Chemotherapy.”